These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 22212696

  • 1. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
    Bai Y, Sun L, Hu S, Wei Y.
    Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis.
    Zhu B, Wang L, Sun L, Cao R.
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):342-6. PubMed ID: 22691882
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL, Chen XY, Li JR, Su SW, Ding T, Shi CX, Jiang YF, Zhu ZN.
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [Abstract] [Full Text] [Related]

  • 4. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG, Ma H, Hu EC, Liu G, Chen G, Xiong CM.
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [Abstract] [Full Text] [Related]

  • 5. The use of combination therapy in pulmonary arterial hypertension: new developments.
    Galiè N, Negro L, Simonneau G.
    Eur Respir Rev; 2009 Sep; 18(113):148-53. PubMed ID: 20956135
    [Abstract] [Full Text] [Related]

  • 6. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension.
    Fox BD, Shimony A, Langleben D.
    Am J Cardiol; 2011 Oct 15; 108(8):1177-82. PubMed ID: 21864815
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
    He CJ, Chen SJ, Wang J, Zhu CY, Yin YH.
    Pulm Pharmacol Ther; 2015 Jun 15; 32():24-8. PubMed ID: 25843006
    [Abstract] [Full Text] [Related]

  • 8. [Endothelin receptor antagonists in pulmonary arterial hypertension].
    Tokgöz HC, Can MM, Kaymaz C.
    Anadolu Kardiyol Derg; 2010 Sep 15; 10 Suppl 2():9-15. PubMed ID: 20819750
    [Abstract] [Full Text] [Related]

  • 9. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
    Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, Musella F, Gargiulo P, Marciano C, Perrone-Filardi P.
    J Am Coll Cardiol; 2012 Sep 25; 60(13):1192-201. PubMed ID: 22995024
    [Abstract] [Full Text] [Related]

  • 10. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU, Schwarz ER.
    Ther Adv Respir Dis; 2013 Feb 25; 7(1):39-49. PubMed ID: 23129569
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Efficacy and safety of sildenafil therapy in pulmonary artery hypertension: a meta-analysis].
    Kuang TG, Wang J, Zhai ZG, Guo XH, Wang C.
    Zhonghua Yi Xue Za Zhi; 2007 Apr 17; 87(15):1021-4. PubMed ID: 17672963
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials.
    Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW.
    Blood Press Monit; 2010 Aug 17; 15(4):195-204. PubMed ID: 20512032
    [Abstract] [Full Text] [Related]

  • 16. Management of pulmonary arterial hypertension.
    Judge EP, Gaine SP.
    Curr Opin Crit Care; 2013 Feb 17; 19(1):44-50. PubMed ID: 23242212
    [Abstract] [Full Text] [Related]

  • 17. Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension.
    Savarese G, Musella F, D'Amore C, Losco T, Marciano C, Gargiulo P, Rengo G, Dellegrottaglie S, Bossone E, Leosco D, Perrone-Filardi P.
    Eur Respir J; 2013 Aug 17; 42(2):414-24. PubMed ID: 23100502
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
    Coeytaux RR, Schmit KM, Kraft BD, Kosinski AS, Mingo AM, Vann LM, Gilstrap DL, Hargett CW, Heidenfelder B, Dolor RJ, McCrory DC.
    Chest; 2014 May 17; 145(5):1055-1063. PubMed ID: 24371842
    [Abstract] [Full Text] [Related]

  • 19. [Update: Current clinical developments in pulmonary hypertension].
    Dumitrescu D, Ghofrani HA, Grimminger F, Hoeper MM, Rosenkranz S.
    Dtsch Med Wochenschr; 2009 Aug 17; 134 Suppl 5():S160-3. PubMed ID: 19718605
    [Abstract] [Full Text] [Related]

  • 20. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.
    Zheng Y, Yang T, Chen G, Hu E, Gu Q, Xiong C.
    Eur J Clin Pharmacol; 2014 Jan 17; 70(1):13-21. PubMed ID: 24026627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.